### Program Objectives:
1. Understand risk factors associated with serotonin syndrome for patients receiving linezolid.
2. Describe the effect of altering clinical pathways, in a manner that de-prioritizes fluoroquinolone use, on prescribing habits of this class of medications in the outpatient setting.
3. Classify the severity of CNI and recall appropriate CNI therapy.
4. Review the published literature supporting tranexamic acid use in massive blood loss secondary to gastrointestinal bleeding and postpartum hemorrhage.
5. Identify the impact of direct pharmacist involvement with the discharge medication reconciliation process.
6. Identify risk factors associated with serotonin syndrome for patients receiving linezolid.
7. Describe the effect of altering clinical pathways, in a manner that de-prioritizes fluoroquinolone use, on prescribing habits of this class of medications in the outpatient setting.
8. Classify the severity of CNI and recall appropriate CNI therapy.
9. Review the published literature supporting tranexamic acid use in massive blood loss secondary to gastrointestinal bleeding and postpartum hemorrhage.
10. Identify the impact of direct pharmacist involvement with the discharge medication reconciliation process.

### Session 1B (7:50 to 9:30) Elkhorn B Critical Care

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentations</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:50</td>
<td>&quot;Impact of Direct Pharmacist Involvement with the Discharge Medication Reconciliation Process&quot;&lt;br&gt;Ahmed Ali (PGY1), St. Joseph Hospital HealthEast - St. Paul, MN</td>
</tr>
<tr>
<td>8:10</td>
<td>&quot;Tranexamic Acid Effect on Mortality in Gastrointestinal Bleeds and Postpartum Hemorrhage&quot;&lt;br&gt;Michael Reichert (PGY1), Wesley Medical Center - Wichita, KS</td>
</tr>
<tr>
<td>8:30</td>
<td>&quot;Evaluation of Interventions &amp; Outcomes in Critically Ill Patients Based on the Use of ICU Confusions Assessment Method (ICAM), Critically Ill Pain Observation Tool (CPOT), Early Mobility, Richmond Agitation &amp; Sedations Scale (RASS); &quot;ICER&quot; Ashley Mulvey (PGY2), Regions Hospital - St. Paul, MN</td>
</tr>
<tr>
<td>8:50</td>
<td>&quot;Comparison of Adverse Medication Event Reporting Systems in a Level 1 Trauma Center&quot;&lt;br&gt;Wrenda Teeple (PGY1), Regions Hospital - St. Paul, MN</td>
</tr>
<tr>
<td>9:10</td>
<td>&quot;Use of Anakinra for HLH/MAS in Pediatric Patients&quot;&lt;br&gt;Anne Zepeski (PGY1), University of Iowa Hospitals and Clinics - Iowa City, IA</td>
</tr>
</tbody>
</table>

### Program Objectives:
1. Identify the impact of direct pharmacist involvement with the discharge medication reconciliation process.
2. Review the published literature supporting tranexamic acid use in massive blood loss secondary to gastrointestinal bleeding and postpartum hemorrhage.
3. Determine if implementation of ICER protocol results in a decreased total length of hospital stay (measured in hours), a decreased total length of ICU stay (measured in hours), decreased time on mechanical ventilation (hours), and decreased mortality rates compared to a historical control group that did not have the ICER protocol (1/1/2015-1/1/2016).
4. Understand potential issues with current reporting systems for adverse medication events.
5. Describe the difference between primary and secondary hemophagocytic lymphohistiocytosis.

### Session 1C (7:50 to 9:30) Elkhorn C Pharmacy Practice

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentations</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:50</td>
<td>&quot;Pharmacist Conducted Patient Education and Discharge Follow-Up in a Rural Hospital Setting&quot;&lt;br&gt;Allison Goedker (PGY1), Lake Region Healthcare - Fergus Falls, MN</td>
</tr>
<tr>
<td>8:10</td>
<td>&quot;Continuous Low Dose Ketamine Infusions in Patients with Uncontrolled Pain&quot;&lt;br&gt;Jeff Engle (PGY1), University of Minnesota Medical Center, Fairview - Minneapolis, MN</td>
</tr>
<tr>
<td>8:30</td>
<td>&quot;Addition of Pharmacist Collaboration to the Medication Reconciliation Process for Home Care Patients&quot;&lt;br&gt;Lauren Kreimer (PGY2), HealthEast Bethesda - Saint Paul, MN</td>
</tr>
<tr>
<td>8:50</td>
<td>&quot;USP &lt;800&gt;: Analysis and Implementation of New Hazardous Drug Handling Requirements&quot;&lt;br&gt;Emily Gjelhaus (PGY1), HealthEast St. John’s Hospital - Maplewood, MN</td>
</tr>
<tr>
<td>9:10</td>
<td>&quot;Implementation and Evaluation of a Pharmacy-Driven Transitions of Care Program Following Emergency Department Visits&quot;&lt;br&gt;Mary Lacy (PGY1), UnityPoint Health Des Moines - Iowa Methodist Medical Center - Des Moines, IA</td>
</tr>
</tbody>
</table>

### Program Objectives:
1. Identify the impact of a pharmacist providing medication education in the inpatient setting.
2. Recognize the utility of ketamine as an adjunctive agent in pain management.
3. Identify specific patient characteristics that a home care clinician can use to identify which patients would receive the most benefit from a pharmacist consultation.
4. Identify common pharmacy practices that are non-compliant with USP <800> and measures to put into place to achieve compliance with USP <800>.
5. Discuss the potential benefits of providing a transitions of care program to patients discharged from the Emergency Department.

### Session 1D (7:50 to 9:30) Big Blue A Primary/Outpatient Care

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentations</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:50</td>
<td>&quot;Implementation and Evaluation of Pharmacy Services and its Effects on Population Health Through The University of Iowa High-Performing Pharmacy Model&quot;&lt;br&gt;Jessica Dixon (PGY2), University of Iowa Hospitals and Clinics - Iowa City, IA</td>
</tr>
<tr>
<td>8:10</td>
<td>&quot;Development and Implementation of a Pharmacist Led Hospital Discharge Medication Reconciliation Process with Student Pharmacist Support&quot;&lt;br&gt;Rachel Lienemann (PGY1), Northeast Iowa Medical Education Foundation - Waterloo, IA</td>
</tr>
<tr>
<td>8:30</td>
<td>&quot;Evaluation of the HealthImpact Diabetes Risk Model Within the VA Health Care System&quot;&lt;br&gt;Jonathan Linder (PGY1), Iowa City VA Health Care System - Iowa City, IA</td>
</tr>
<tr>
<td>8:50</td>
<td>&quot;Evaluation of Veterans at Risk for Hypoglycemia at the Iowa City Veterans Affairs Health Care System&quot;&lt;br&gt;Andrea Flanagan (PGY1), Iowa City VA Health Care System - Iowa City, IA</td>
</tr>
<tr>
<td>9:10</td>
<td>&quot;Pharmacist-Led Medication Education in a Cardiac Rehabilitation Program to Reduce 30-Day Hospital Readmissions&quot;&lt;br&gt;Kayla Stein (PGY1), Covenant Medical Center - Waterloo, IA</td>
</tr>
</tbody>
</table>

### Program Objectives:
1. Describe how enhanced pharmacy services can impact population health management and improve patient outcomes, quality of care, and decrease total cost of care.
2. Determine which outcomes are improved with pharmacist-led medication reconciliation programs.
3. Recognize how HealthImpact’s design is unique compared to previous diabetes risk models.
4. Determine if rate of veterans at risk for hypoglycemia at Iowa City VA based on the Veterans Health Administration Hypoglycemic Safety Initiative definition has changed since December 31, 2010.
5. Describe the impact of pharmacist-led medication education and intervention in a cardiac rehabilitation program through use of patient surveys and 30-day readmission rates.
**THURSDAY, MAY 11, 2017**

### Program Objectives:

1. Describe risk factors for the progression of upper respiratory tract infection to lower respiratory tract infection and death in post-hematopoietic cell transplant recipients.
2. Define cutaneous reactions associated with pemtrexed treatment and identify the impact of cyanocobalamin timing on hematologic toxicities resulting from pemtrexed.
3. Express the importance of tacrolimus in patients after allogeneic hematopoietic cell transplantation.
4. Describe guideline recommendations for how patients with febrile neutropenia without clinically documented infection should be treated.
5. Discuss appropriate use of steroids for management of immune-related adverse effects of checkpoint inhibitors and their associated toxicities.

### Session 1E (7:50 to 9:30)

#### Big Blue B

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:50 to 8:10</td>
<td>Validation of an Immunodeficiency Scoring Index for Respiratory Syncytial Virus Used to Predict Progression from Upper to Lower Respiratory Tract Infection in Patients With Hematopoietic Cell Transplant Recipients</td>
<td>Marissa Olson (PGY2), Barnes-Jewish Hospital - Saint Louis, MO</td>
</tr>
<tr>
<td>8:10 to 8:30</td>
<td>Management of Pemtrexed Associated Toxicities*</td>
<td>Laura Prohaska (PGY2), The University of Kansas Health System - Kansas City, KS</td>
</tr>
<tr>
<td>8:30 to 8:50</td>
<td>Risk Factors for Subtherapeutic Tacrolimus Levels After Conversion from Continuous Intravenous Infusion to Oral in Adults Post-Allogeneic Hematopoietic Cell Transplantation*</td>
<td>Kelsey Konradny (PGY2), The University of Kansas Health System - Kansas City, KS</td>
</tr>
<tr>
<td>8:50 to 9:10</td>
<td>Evaluation of Antibiotic Use in Febrile Neutropenia Patients with Acute Myelogenous Leukemia without a Clinically Documented Infection*</td>
<td>Stephen Andrews (PGY1), The University of Kansas Health System - Kansas City, KS</td>
</tr>
<tr>
<td>9:10 to 9:30</td>
<td>Evaluation of Corticosteroids for the Management of Immune-Related Adverse Events in Patients Receiving Checkpoint Inhibitors*</td>
<td>Kiersten Williams (PGY2), The University of Kansas Health System - Kansas City, KS</td>
</tr>
</tbody>
</table>

### Session 1F (7:50 to 9:30)

#### Big Blue C

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:50 to 8:10</td>
<td>Evaluation of Pharmacist’s Clinical Interventions at a Community Hospital*</td>
<td>Yunhsuan Hoover (PGY1), Olathe Health - Olathe, KS</td>
</tr>
<tr>
<td>8:10 to 8:30</td>
<td>Impact of Medication Tracking on Medication Distribution*</td>
<td>Christine Koves (PGY1), United Hospital - St. Paul, MN</td>
</tr>
<tr>
<td>8:30 to 8:50</td>
<td>Technical, Operational, Safety, and Budget Considerations for Selection and Implementation of IV Workflow Automation in an Academic Medical Center*</td>
<td>Brianne Bakken (PGY2), University of Iowa Hospitals and Clinics - Iowa City, IA</td>
</tr>
<tr>
<td>8:50 to 9:10</td>
<td>Design &amp; Implementation of a Discharge Medication Reconciliation Process for Health System*</td>
<td>Sergey Brenda (PGY1), Fairview Northland Medical Center - Princeton, MN</td>
</tr>
<tr>
<td>9:10 to 9:30</td>
<td>The Impact of Monthly Pharmacy Performance Email Communications on Medication Therapy Management Activity*</td>
<td>Nashmi Albadarin (PGY1), OutcomesMTM - Clive, IA</td>
</tr>
</tbody>
</table>

### Session 1G (7:50 to 9:30)

#### Council Bluffs A

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:50 to 8:10</td>
<td>Comparison of Time to In-Hospital Venous Thromboembolism in Obese Patients*</td>
<td>Tate Cutsahl (PGY2), Houston Methodist Hospital - Houston, TX</td>
</tr>
<tr>
<td>8:10 to 8:30</td>
<td>A Point Prevalence Study of Sequential Compression Device Compliance*</td>
<td>Ekin Ekinci (PGY1), Houston Methodist Hospital - Houston, TX</td>
</tr>
<tr>
<td>8:30 to 8:50</td>
<td>Direct Oral Anti-coagulants versus Aspirin for Venous Thromboembolism Prophylaxis After Orthopedic Surgery*</td>
<td>Tianrui Yang (PGY1), Houston Methodist Hospital - Houston, TX</td>
</tr>
<tr>
<td>8:50 to 9:10</td>
<td>Comparison of Safety and Efficacy Between Two Adult Insulin Infusion Protocols at a Community Hospital*</td>
<td>Brady Lewis (PGY1), Mercy Hospital Joplin - Joplin, MO</td>
</tr>
<tr>
<td>9:10 to 9:30</td>
<td>An Analysis of Elderly Veterans Who Remain on Antihypertensive Medications While Experiencing Hypotension*</td>
<td>Megan Michaelson (PGY1), Fargo Veterans Affairs Health Care System - Fargo, ND</td>
</tr>
</tbody>
</table>

### Session 1H (7:50 to 9:30)

#### Council Bluffs B

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:50 to 8:10</td>
<td>Effectiveness of an Academic Detailing Program on Antibiotic Use in Outpatient Urinary Tract Infections*</td>
<td>Geena Hopwood (PGY1), VA Central Iowa Health Care System - Des Moines, IA</td>
</tr>
<tr>
<td>8:10 to 8:30</td>
<td>Implementation of the Veteran Health Administration’s Hypoglycemia Safety Initiative: A Focus on Patient Safety*</td>
<td>Christy Marchiando (PGY1), VA Central Iowa Health Care System - Des Moines, IA</td>
</tr>
<tr>
<td>8:30 to 8:50</td>
<td>Streamlining Medication Lists on Discharge/Transfer from the Community Living Center (CLC) in a VA Medical Center*</td>
<td>Emily Eddy (PGY1), VA Nebraska-Western Iowa Health Care System - Grand Island, NE</td>
</tr>
<tr>
<td>8:50 to 9:10</td>
<td>Evaluation of a Pharmacist-Run Direct Oral Antiocoagulant (DOAC) Monitoring Clinic at a Veteran Affairs Healthcare System*</td>
<td>Shayla Bigley (PGY1), VA Nebraska-Western Iowa Health Care System - Grand Island, NE</td>
</tr>
<tr>
<td>9:10 to 9:30</td>
<td>Assessing PEG Scores During a Pharmacist Managed Opioid Taper*</td>
<td>Ashley Lane (PGY1), Minneapolis Veterans Affairs Health Care System - Minneapolis, MN</td>
</tr>
</tbody>
</table>

### Session 1I (7:50 to 8:10)

#### Missouri

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:50 to 8:10</td>
<td>Effects of Ketamine in Patients with Cardiovascular Comorbidities*</td>
<td>Leigh Gomez (PGY2), Nebraska Medicine - Omaha, NE</td>
</tr>
</tbody>
</table>

Program Objectives:

1. Describe the pharmacological effects of ketamine and why some are concerned about using this drug in patients with cardiovascular comorbidities.
THURSDAY, MAY 11, 2017

**Session 1J (7:50 to 8:10)**
Platte  Psych

7:50 to 8:10 “Review of Gabapentin Efficacy for Behavioral Symptoms in a Geriatric Psychiatric Population”  
Gerard Kokett (PGY2), Avera Behavioral Health Center - Sioux Falls, SD

**Program Objectives:**
1. Describe potential benefits of gabapentin in the treatment behavioral and psychotic symptoms of dementia (BPSD).

---

**Session 2A (10:50 to 11:50)**
Elkhorn A  Infectious Disease

10:50 to 11:10 “Evaluation of Current Procalcitonin Usage at Community Teaching Hospital”  
Daphne Goewey (PGY1), SSM Health St Mary’s Hospital - Richmond Heights, MO

11:10 to 11:30 “Evaluation of the Use of Daptomycin Plus Ceftriaxone for the Treatment of Multi-Drug Resistant Staphylococcal and Enterococcal Infections”  
Amanda Bozell (PGY1), St. John Medical Center - Tulsa, OK

11:30 to 11:50 “Evaluation of Differences in Efficacy and Efficiency Between Three Electrolyte Replacement Protocols”  
Kent Bridgeman (PGY1), Mercy Hospital - Allina Health - Coon Rapids, MN

**Program Objectives:**
1. Describe current usage patterns of procalcitonin at SSM Health St Mary’s as well as benefits and limitations of the current send out lab.
2. Discuss potential adverse events that may arise from daptomycin plus ceftriaxone therapy.
3. Describe potential benefits of evaluating standardized protocols used within a health system.

---

**Session 2B (10:50 to 11:50)**
Elkhorn B  Critical Care

10:50 to 11:10 “Continuation of Antipsychotic Treatment Following Initiation in an Intensive Care Unit”  
Eric Hamilton (PGY1), UAMS - Little Rock, AR

11:10 to 11:30 “Fixed versus Variable Dosing of 4-Factor Prothrombin Complex Concentrate for the Reversal of Warfarin-Related Non-Intracranial Bleeding”  
Angelika Cyganska (PGY1), Saint Luke's Hospital - Kansas City, MO

11:30 to 11:50 “Pharmacist Interventions in the Emergency Department and Associated Medication Error Prevention and Cost Avoidance”  
Lynsee Lanners (PGY1), Saint Luke’s Hospital of Kansas City - Kansas City, MO

**Program Objectives:**
1. Describe the recommended assessment tools used for detection and monitoring of ICU-delirium.
2. Discuss the impact of the implementation of a lower fixed-dose 4-factor prothrombin complex concentrate protocol on clinical outcomes and cost effectiveness.
3. Describe types of pharmacist interventions made in the emergency department.

---

**Session 2C (10:50 to 11:50)**
Elkhorn C  Pharmacy Practice

10:50 to 11:10 “Impact of Pharmacist-Lead Nursing Education on the Incidence of ICU Delirium in Mechanically-Ventilated Adult Patients”  
Timothy Johnson (PGY1), St. Luke’s Hospital - Duluth, MN

11:10 to 11:30 “Impact of Admission Pharmacy Services on Patient Care Transitions in a Community Hospital Setting”  
Lauren Fox (PGY1), CoxHealth - Springfield, MO

11:30 to 11:50 “Improving Home Naloxone Rescue Kit Availability and Education”  
Rose Fitzgerald (PGY1), VA Black Hills Health Care System - Fort Meade, SD

**Program Objectives:**
1. Identify recommended interventions on how to decrease the amount of sedation used in mechanically-ventilated ICU patients.
2. Review contributory factors for an increased number of discrepancies on a patient’s prior to admission medication list.
3. Identify risk factors for opioid overdose.

---

**Session 2D (10:50 to 11:50)**
Big Blue A  Primary/Ambulatory Care

10:50 to 11:10 “Predictors of Dimethyl Fumarate-Induced Lymphocytopenia”  
Emily Prinz (PGY2), University of Iowa Hospitals and Clinics - Iowa City, IA

11:10 to 11:30 “Improving Patient Safety During Transitions From Hospital to Long-Term Care Facility”  
Emily Ansolabehere (PGY1), University of Iowa Hospitals and Clinics - Iowa City, IA

11:30 to 11:50 “Assessing the Frequency of Amiodarone Adverse Drug Effect Monitoring at an Academic Medical Center”  
Eva Coulson (PGY1), University of Iowa Hospitals and Clinics - Iowa City, IA

**Program Objectives:**
1. Recognize the importance of identifying risk factors that could potentially put an individual at increased risk for lymphocytopenia while taking dimethyl fumarate for multiple sclerosis.
2. Identify potential drug-related problems/medication errors that may occur during patient’s transition from acute care to long-term care & opportunities for process improvement related to transition
3. Identify the important baseline and follow-up monitoring that should be actively followed in long term amiodarone medication use.

---

**Session 2E (10:50 to 11:50)**
Big Blue B  Community Practice

10:50 to 11:10 “Process Improvement of Outpatient Pharmacy Charge Accounts”  
Jason Kim (PGY1), The University of Kansas Health System - Kansas City, KS

11:10 to 11:30 “Effects of Increased Naloxone Access Due to the Expanding Role of Pharmacists”  
Megan Trout (PGY1), Thrifty White Pharmacy - Fargo, ND

11:30 to 11:50 “Implementation of an Intensive Lifestyle Intervention Program to Prevent Type 2 Diabetes Mellitus”  
Aiycee Ansolabehere (PGY1), Ball’s Food Stores - Kansas City, KS

**Program Objectives:**
1. Establish criteria and policy in a charge account program giving set standards on its utilization, assessed by pre and post intervention data.
2. After this presentation you will be able to identify individuals recommended to receive naloxone due to the risk of overdose.
3. Review the requirements to become a recognized provider of the CDC Diabetes Prevention Program.

---

**Session 2F (10:50 to 11:50)**
Big Blue C  Pediatrics/Neonatology

10:50 to 11:10 “Implementation of a Pediatric Acute Kidney Injury Scoring System”  
Melissa Sanders (PGY1), University of Minnesota Medical Center - St. Paul, MN

11:10 to 11:30 “Levetiracetam versus Lorazepam as Abortive Therapy in Breakthrough Seizures in Pediatric Patients”  
Jordan Snyder (PGY1), Wesley Medical Center - Wichita, KS

11:30 to 11:50 “Potential Risk Factors Associated with Repeated Systemic Corticosteroids After a Single Dose of Dexamethasone During Acute Asthma Exacerbations”  
Coty Tunwar (PGY1), Wesley Medical Center - Wichita, KS

**Program Objectives:**
1. By the end of this presentation, the audience will be able to define acute kidney injury in the pediatric population and will be able to determine high nephrotoxic medication exposure.
2. Identify the most effective and safest agent to use in pediatric patients as abortive therapy during breakthrough seizures.
3. Review literature comparing dexamethasone versus prednisone use in pediatric patients for asthma exacerbation.
THURSDAY, MAY 11, 2017

Session 2G (10:50 to 11:50) Council Bluffs A Psych

10:50 to 11:10 Evaluation of an Outpatient Pharmacy-Mediated Service to Reduce Benzodiazepine Use in Patients with Dementia
Joseph Sodor (PGY1), Veterans Affairs Nebraska-Western Iowa Healthcare System - Omaha, NE

11:10 to 11:30 Monitoring the Impact on Seizure Duration of Holding, Dose Reducing, or Continuing Anticonvulsant Medications Prior to Electroconvulsive Therapy (ECT)
Haylee Brodersen (PGY1), Avera McKennan Hospital & University Health Center - Sioux Falls, SD

11:30 to 11:50 Implementation of an Inomnia Order Set to Reduce Chronic Benzodiazepine Use
Martin Bloch (PGY1), Minneapolis Veterans Affairs Healthcare System - Minneapolis, MN

Program Objectives:
1. Identify appropriate BZD taper recommendations as well as alternative agents to use for the treatment of agitation, anxiety, and insomnia in patients with dementia.
2. Recognize anticonvulsant medications that have the potential to decrease ECT seizure duration.
3. Identify the recommended first-line treatment for insomnia.

Session 2H (10:50 to 11:50) Council Bluffs B Transplant

10:50 to 11:10 Rabbit Antithymocyte Globulin for the Treatment of Chronic Lung Allograft Dysfunction
Spenser January (PGY2), Barnes-Jewish Hospital - St. Louis, MO

11:10 to 11:30 Effects of the Addition of Mycophenolate Mofetil on Patient Outcomes in Liver Transplant Recipients
Molly Polzin (PGY1), Nebraska Medicine - Omaha, NE

11:30 to 11:50 Evaluation of Cytomegalovirus Prophylaxis Regimens in Intestinal Transplant Recipients: A Single Center Experience
Meagan Eley (PGY2), Nebraska Medicine - Omaha, NE

Program Objectives:
1. Describe the patient characteristics associated with a decreased response to rabbit antithymocyte globulin (rATG) in the treatment of chronic lung allograft dysfunction (CLAD).
2. Identify the benefit of the addition of mycophenolate mofetil (MMF) to tacrolimus-based immunosuppression regimens post-transplant.
3. Describe the role of antiviral medications in intestinal transplant recipients for the prevention of CMV infection post-transplant.

Session 3A (1:10 to 2:50) Elkhorn A Infectious Disease

1:10 to 1:30 Antimicrobial Stewardship in a Community Hospital: Measuring the Impact of Pharmacist Interventions
Rebecca Wienenbar (PGY1), Mercy Hospital - Allina Health - Minneapolis, MN

1:30 to 1:50 Empiric Antibiotic Therapy Selection in Penicillin Allergic Patients Presenting with Sepsis
Benjamin Yun (PGY1), Park Nicollet Methodist Hospital - St. Louis Park, MN

1:50 to 2:10 Pre and Post Evaluation of a Pharmacist-Driven Procalcitonin Collaborative Practice Agreement
Ty Drake (PGY1), UnityPoint Health - Methodist - Des Moines, IA

2:10 to 2:30 Vancomycin Pharmacokinetic Dosing: Impact of a Pharmacokinetic Standardized Method on Achieving Therapeutic Vancomycin Goals
Brian Dalke (PGY1), Veterans Affairs Nebraska-Western Iowa Healthcare System - Omaha, NE

2:30 to 2:50 Evaluating Ledipasvir/Sofosbuvir Sustained Viral Response in a Veteran Population
Allyson Cord (PGY1), Veterans Affairs Nebraska-Western Iowa Healthcare System - Omaha, NE

Program Objectives:
1. State the benefits of an antimicrobial stewardship program.
2. Identify appropriate patients that should be initiated on alternative antibiotics due to a penicillin allergy.
3. Describe procalcitonin's role in antimicrobial stewardship.
4. Discuss pharmacokinetic parameters altered in obese patients and how this can affect vancomycin dosing.
5. Explain the significance of achieving a sustained Hepatitis C viral response at 12 weeks following completion of therapy.

Session 3B (1:10 to 2:50) Elkhorn B Critical Care

1:10 to 1:30 Delirium in the Intensive Care Unit: A Healthcare Team Collaboration for Prevention and Management
Carrie Spindler (PGY1), North Memorial Medical Center - Robbinsdale, MN

1:30 to 1:50 Tranexamic Acid Protocol Completion Rates of Trauma Patients Presenting by Emergency Medical Services to a Community Level-One Trauma Center
Emily Grgic (PGY1), North Memorial Medical Center - Robbinsdale, MN

1:50 to 2:10 Ketamine as an Analgesia Adjuvant in Trauma ICU Patients
Mary Walters (PGY1), North Memorial Medical Center - Robbinsdale, MN

2:10 to 2:30 A Prospective, Randomized Study of Fixed versus Variable Dosing of 4-Factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal at a Large Tertiary Care Medical Center
Brandon Van Amber (PGY1), Regions Hospital - St. Paul, MN

2:30 to 2:50 Developing a Pharmacists-Based Advanced Cardiac Life Support Training Module
David Green (PGY1), Allina Health- Mercy Hospital - Coon Rapids, MN

Program Objectives:
1. Identify high risk criteria that are associated with the development of delirium as defined in the Pain, Agitation, and Delirium Guidelines.
2. Recognize the importance of protocol completion for tranexamic acid and indicate why the rate of completion is low at the institution at which it was studied.
3. Identify appropriate trauma patient populations in which adjuvant low dose ketamine could be used to help modulate pain.
4. Recognize the use of fixed dose 4FPCP for reversal of warfarin-induced anticoagulation for emergent bleed or surgery.
5. Identify pharmacist advanced cardiac life support competency skill areas in need of improvement and outline ways these skill areas can be improved in a training module.

Session 3C (1:10 to 2:50) Elkhorn C Pharmacy Practice

1:10 to 1:30 Alcohol and Illegal Drug Use in US High School Aged Youth: Impact on Violence-Related Behaviors and Suicide Ideation
Mary Heiken (PGY1), Essentia Health - Brainerd, MN

1:30 to 1:50 Prevalence of Patients Presenting to Emergency Departments with ST Elevated Myocardial Infarctions (STEMI) in the United States Receiving Parenteral Anticoagulants Before Hospitalization
Kevin Heald (PGY1), Essentia Health - Brainerd, MN

1:50 to 2:10 Utilization of Lockboxes for Controlled Medications to Reduce Drug Diversion and Prevent Accidental Overdose
Giau Phan (PGY1), St. John Medical Center - Tulsa, OK

2:10 to 2:30 Effectiveness of Umecrilinium-Vilanterol for Protocolized Management of Chronic Obstructive Pulmonary Disease Exacerbation in Hospitalized Patients
Todd Chapin (PGY1), Sanford Medical Center Fargo - Fargo, ND

2:30 to 2:50 Review of Adult Sexual Assault Treatment Protocol Compliance at an Academic Medical Center's Emergency Department
Amber Olson (PGY1), Nebraska Medicine - Omaha, NE

Program Objectives:
1. Understand the pharmacist’s role in mental health status improvement and prevention of substance abuse in US high school aged youth.
2. Describe trends in treatment of STEMI within the United States and ways to reduce and/or eliminate disparities.
3. Discuss the statewide and national problems regarding prescription drug abuse.
5. Identify the current compliance rate of the electronic adult sexual assault treatment protocol at an academic medical center's emergency department.
1. Recognize the recommended anticoagulants for the prevention of venous thromboembolism (VTE) in patients with malignancies.

2. Describe possible cardiomyopathy prevention strategies related to hyperlipidemia in patients receiving anthracycline-based chemotherapy.

3.Discriminate the differences between the guideline definition and clinical definition of neutropenia.

Program Objectives:
1. Identify patient indications for use of statin therapy for secondary ASCVD prevention.
2. Recognize risk factors for hypoglycemia as identified by the National HSI tool used by the VA.
3. Identify preventable medication-related risks commonly associated with hospitalization in older adults.
4. Describe the advantages and drawbacks of utilizing glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter-2 inhibitors for the management of type 2 diabetes mellitus.
5. Understand the dangers of co-prescribing opioids with benzodiazepines.

Session 3E (1:10 to 2:50)

1. Single-center Experience with Epstein-Barr Virus Screening in Lung Transplant Recipients to Identify Patients with Post-Transplant Lymphoproliferative Disorder
   - Derek Owen (PGY2), Houston Methodist Hospital - Houston, TX

2. The Incidence and Outcomes of Fever of Unknown Origin after Pancreas Transplantation
   - Robin Klasen (PGY2), Houston Methodist Hospital - Houston, TX

3. The Effect of Pre-Heart Transplantation Amiodarone Use on Primary Graft Dysfunction
   - Mallory Crain (PGY1), Barnes-Jewish Hospital - St. Louis, MO

4. Influence of Pre-Transplant Middriode or Fluorocortisone Use on Graft-Related Outcomes After Kidney Transplantation
   - April Pottebaum (PGY2), Barnes-Jewish Hospital - St. Louis, MO

5. Clinical Outcomes of LCP-Tacrolimus (Envarsus, Once Daily) versus Tacrolimus IR (Twice Daily) in De Novo Kidney Transplant Recipients in the United States
   - Katie McMurty (PGY1), Barnes-Jewish Hospital - St. Louis, MO

Program Objectives:
1. Identify lung transplant recipients who are at risk for developing Post-Transplant Lymphoproliferative Disorders using plasma Epstein-Barr Virus titers.
2. To describe the incidence and outcomes of pancreas recipients developing fever of unknown origin (FUO) during the first post-transplant year.
3. Discuss amiodarone toxicity in relation to dosing and how this affects primary graft dysfunction.
4. Describe the influence of pre-transplant middriode or fluorocortisone use on graft-related outcomes after kidney transplantation.
5. To compare and contrast the immediate release formulation of tacrolimus (Prograf) with the extended release formulation (tacrolimus XR, Envarsus).

Session 3F (1:10 to 2:50)

1. Evaluation of a Pharmacist-Driven Continuous Infusion Unfractionated Heparin Protocol
   - Stephanie Willis (PGY1), Nebraska Medicine - Omaha, NE

2. Strategies to Decrease Intravenous Waste in the Inpatient Pharmacy
   - Brett Bailey (PGY1), UAMS - Little Rock, AR

3. Evaluation of Screening Parameter Compliance for Specialty Medication Initiation Before and After Quality Improvement Implementation within a Rheumatology Clinic in an Academic Health System
   - Daniel Peterson (PGY1), University of Iowa Hospitals and Clinics - Iowa City, IA

4. Effectiveness of a Pharmacist-Driven Process for Timing Drug Assays
   - Jonathan Wilson (PGY1), University of Iowa Hospitals and Clinics - Iowa City, IA

5. Improving the Quality of Diagnosing Heparin-Induced Thrombocytopenia at an Academic Medical Center
   - Ivana Bogdanich (PGY1), University of Iowa Hospitals and Clinics - Iowa City, IA

Program Objectives:
1. Describe the impact of establishing a pharmacist-driven continuous infusion UFH protocol at an academic medical center.
2. Identify identification strategies that can potentially decrease IV medication waste in the inpatient pharmacy setting.
3. Identify pertinent patient laboratory tests when assessing whether a given specialty medication is clinically appropriate to initiate.
4. Describe the impact of implementing a drug assay reminder workflow utilizing the electronic medical record on the percentage of drug levels drawn appropriately and at the intended time.
5. Outline the 4-Ts in the pretest scoring system and their predictive value for HIT.

Session 3G (1:10 to 2:50)

1. Comparison of Time to Absolute Neutrophil Count Recovery in Patient who Received Filgrastim or tbo-filgrastim
   - Nan Patterson (PGY1), Saint Francis Hospital - Tulsa, OK

2. Role of Hyperlipidemia in Anthracycline-Induced Cardiomyopathy
   - Cora Housley (PGY1), University of Missouri Health Care - Columbia, MO

3. Failure Rates of Parenteral versus Direct-Oral Anticoagulants in Patients with Malignancies
   - Samantha Maples (PGY1), Via Christi Hospitals Wichita, Inc. - Wichita, KS

4. Evaluation of Pharmacy to Dose Heparin Drip Protocol at a Community Hospital
   - Tandinh Pham (PGY1), Freeman Health System - Joplin, MO

5. Comparison of Neutropenic Fever Antimicrobial Management in Immunocompromised Patients Under Hematology/Oncology and Hospitalist Services
   - Kelsey Johnson (PGY1), Mercy Hospital Springfield - Springfield, MO

Program Objectives:
1. Discriminate the differences between the guideline definition and clinical definition of neutropenia.
2. Describe possible cardiomyopathy prevention strategies related to hyperlipidemia in patients receiving anthracycline-based chemotherapy.
3. Recognize the recommended anticoagulants for the prevention of venous thromboembolism (VTE) in patients with malignancies.
4. Review pharmacy to dose heparin drip protocol at a community hospital, benefits, and obstacles associated with the department’s workflow.
5. Review the recommendations of the IDSA guidelines for treatment of neutropenic fever in immunocompromised patients.
THURSDAY, MAY 11, 2017

Session 3H (1:10 to 2:50) Council Bluffs B Infectious Disease

1:10 to 1:30  “Effect of an Electronic Health Record Alert to Prescribers on De-escalation of Antimicrobial Therapy”
Emily Endres (PGY1), Mercy Hospital Springfield - Springfield, MO

1:30 to 1:50  “Impact of Vancocycin Use in Community-Acquired Pneumonia in Hospitalized Native American Patients”
Jessica Rounds (PGY1), Rapid City Regional Health - Rapid City, SD

1:50 to 2:10  “Implementation of a Pharmacy Protocol for Intravenous to Oral Conversion of Similar Antibiotics in the Hospital Setting”
Charles Morrison (PGY1), Rapid City Regional Hospital - Rapid City, SD

2:10 to 2:30  “Assessment of Piperacillin-Tazobactam Utilization in a Community Hospital”
Natalie Vasant (PGY1), SSM Health St Clare Hospital - Fenton, MO

2:30 to 2:50  “Evaluation of a Pharmacist-led Vancomycin Dosing Service in the Management of Obese versus Non-obese Patients”
Molly Grasberger (PGY1), Saint Francis Hospital - Tulsa, OK

Program Objectives:
1. Discuss the impact of an electronic health record alert to prescribers on de-escalation of antimicrobial therapy.
2. Describe the prevalence of methicillin resistant staphylococcus aureus (MRSA) among hospitalized cases of community-acquired pneumonia.
3. Identify reasons to consider transitioning patients from intravenous antimicrobial therapy to oral antimicrobial therapy.
4. Recognize appropriate dosing of piperacillin-tazobactam based on a patient’s renal function.
5. Describe factors impacting vancomycin dosing in obese patients.

Session 3I (2:10 to 2:50) Missouri Transplant

2:10 to 2:30  “Financial and Safety Analysis for Conversion of Generic USP Modified Cyclosporine Manufacturers in Solid Organ Transplant Recipients”
Logan Glyten (PGY1), University of Minnesota Medical Center - Minneapolis, MN

2:30 to 2:50  “Effects of Clotrimazole Troches on Tacrolimus Dosing in Orthotopic Heart Transplant”
Melissa Laub (PGY1), Mayo Clinic Hospital - Rochester - Rochester, MN

Program Objectives:
1. Compare serum drug concentration and renal function after transition of manufacturers of immune suppressant medication.
2. Identify the potential clinical effects of clotrimazole discontinuation in transplant patients.

Session 3J (2:10 to 2:50) Platte Pediatrics/Neonatology

2:10 to 2:30  “Retrospective Review of Data to Compare the Effects of Various Continuous Sedation Methods on Hemodynamics, Sedation Level, Recovery Period, and Complications in Pediatric Patients”
Hubert Lahr (PGY1), Avera McKennan Hospital & University Health Center - Sioux Falls, SD

2:30 to 2:50  “Evaluation of Gentamicin Dosing Protocol in the Neonatal Intensive Care Unit (NICU)”
Abigail Mott (PGY1), Saint Luke’s Hospital - Kansas City, MO

Program Objectives:
1. Compare the clinical outcomes of different continuous sedation methods in the pediatric population.
2. Outline the evaluation of SLHS original neonatal gentamicin dosing protocol compared to the newly adopted NeoFax protocol.

Session 4A (3:00 to 4:20) Elkhorn A Infectious Disease

3:00 to 3:20  “Evaluation of Orallyavancin and Dalbavancin as Cost-Effective Treatments of Acute Bacterial Skin and Soft Tissue Infections (ABSSSI)”
Christina Koutsari (PGY1), Abbott Northwestern Hospital - Minneapolis, MN

3:20 to 3:40  “Improving Carbapenem Stewardship for Empiric Treatment Of ESBL-Producing Bacterial Infections”
Lina Hamid (PGY1), Abbott Northwestern Hospital - Minneapolis, MN

3:40 to 4:00  “Pharmacist-Driven Intervention and Duration of Antimicrobial Therapy for Pneumonia at Hospital Discharge”
Lisa Phan (PGY1), Olathe Health - Olathe, KS

4:00 to 4:20  “Impact of Required Indications on Carbapenem Prescribing”
Sydney Johnk (PGY1), Sanford Medical Center Fargo - Fargo, ND

Program Objectives:
1. Identify common pathogens of ABSSSI.
2. Identify common risk factors associated with ESBL-producing bacterial infections.
3. Discuss recommended durations of antimicrobial therapy for community-acquired pneumonia and healthcare-associated pneumonia.
4. Recognize appropriate use of a carbapenem for empiric therapy of a nosocomial infection.

Session 4B (3:00 to 4:20) Elkhorn B Critical Care

3:00 to 3:20  “Intentional Opioid Overdose: A Population Based Cross-Sectional Study of Disparities in Patients Presenting to an Emergency Department in the United States”
Amber Soukkala (PGY1), Essentia Health - Duluth, MN

3:20 to 3:40  “Are There Population Disparities in the Receipt of Tissue Plasminogen Activator (tPA) Among Adults Presenting to an Emergency Department (ED) with Acute Ischemic Stroke?”
Montana Hemling (PGY1), Essentia Health - St. Joseph’s Medical Center - Brainerd, MN

3:40 to 4:00  “Discharge Prescribing Trends of Benzodiazepines for Anxiety in Emergency Departments in the United States”
Catherine Olson (PGY1), Essentia Health - St. Mary’s Medical Center - Duluth, MN

4:00 to 4:20  “Sedation Practices in Mechanically Ventilated Patients in a Community Hospital Intensive Care Unit”
Emily Wiederanders (PGY1), SSM Health St Clare Hospital - Fenton, MO

Program Objectives:
1. Describe population disparities that exist for patients who present to EDs in the US due to intentional opioid overdose.
2. Review eligibility criteria for treatment of acute ischemic stroke with tissue plasminogen activator (tPA).
3. Understand the prevalence of benzodiazepine use in the United States as well as the trends in their use for the treatment of anxiety in an emergency department setting.
4. Explain the importance of limiting over-sedation of mechanically ventilated patients in the intensive care unit.

Session 4C (3:00 to 4:20) Elkhorn C Pharmacy Practice

3:00 to 3:20  “Analysis of Reimbursement for Medications Administered in an Outpatient Infusion Clinic Associated with an Academic Medical Center”
Jordan Carter (PGY1), The University of Kansas Health System - Kansas City, KS

3:20 to 3:40  “Controlled Substance Handling in the Perioperative Area Following Implementation of Anesthesia Workstations”
Janelle Rychnik (PGY2), The University of Kansas Health System - Kansas City, KS

3:40 to 4:00  “Impact and Implementation of Offsite Pharmacy Service Center”
Montana Hemling (PGY1), Essentia Health - St. Joseph’s Medical Center - Brainerd, MN

4:00 to 4:20  “Impact and Implementation of Offsite Pharmacy Service Center”
Lauren Edwards (PGY1), The University of Kansas Health System - Kansas City, KS

Program Objectives:
1. Identify potential deficiencies in the precertification process that could result in a rejected claim.
2. Recognize the impact anesthesia workstations had on the anesthesia providers’ workflow related to controlled substance handling.
3. Describe potential interventions pharmacists can make in pain management.
4. The main objectives for this presentation are to identify the medications currently being outsourced to Pharmedium and determine if re-insourcing these products would benefit the health system.
### Program Objectives:

1. Understand the purpose of measuring patient satisfaction for Medication Therapy Management services.
2. Describe the potential benefits of providing pharmacist Comprehensive Medication Reviews in a primary care clinic.
3. Describe the potential benefits of having a pharmacist-managed outpatient formulary system in place.
4. Describe the impact of pharmacist-provided comprehensive medication review (CMR) for patients receiving oral chemotherapy.

### Program Objectives:

1. Recognize commonly documented side effects of stimulant medications.
2. Recognize risk factors that put neonates at risk of aluminum toxicity.
4. Recognize commonly used substances during pregnancy associated with Neonatal Abstinence Syndrome.

### Program Objectives:

1. Identify appropriate anticoagulation based on risk factor evaluation for multiple myeloma patients treated with either lenalidomide or pomalidomide.
2. Describe the development and implementation of a pharmacist role, collaboratively defined by pharmacy and hospitalist departments, and the subsequent impact on safe medication utilization in a community hospital.
3. Recognize appropriate management of immune related adverse effects due to PD-1 and PD-L1 therapy.
4. Evaluate the effect of tbo-filgrastim (Granix®) vs filgrastim (Neupogen®) on CD34+ counts during stem cell mobilization & neutrophil engraftment in hematopoietic stem cell transplant patients at Avera McKennan Hospital and University Health Center: A Retrospective Review.

### Program Objectives:

1. Identify the proper statin dose for patients 75 years or older, for diabetics, and for patients with a history of clinical ASCVD.
2. Know what parameters are used to calculate ASCVD risk.
3. Identify the most common reasons that patients are not on GDMT or sub-optimal GDMT.

### Program Objectives:

1. Recognize appropriate anticoagulation based on risk factor evaluation for multiple myeloma patients treated with either lenalidomide or pomalidomide.
2. Describe the development and implementation of a pharmacist role, collaboratively defined by pharmacy and hospitalist departments, and the subsequent impact on safe medication utilization in a community hospital.
3. Recognize appropriate management of immune related adverse effects due to PD-1 and PD-L1 therapy.
4. Evaluate the effect of tbo-filgrastim (Granix®) vs filgrastim (Neupogen®) on CD34+ counts during stem cell mobilization & neutrophil engraftment in hematopoietic stem cell transplant patients at Avera McKennan Hospital and University Health Center: A Retrospective Review.

### Program Objectives:

1. Identify the proper statin dose for patients 75 years or older, for diabetics, and for patients with a history of clinical ASCVD.
2. Know what parameters are used to calculate ASCVD risk.
3. Identify the most common reasons that patients are not on GDMT or sub-optimal GDMT.
4. Discuss the importance of effective anticoagulation in obese patients.

---

**THURSDAY, MAY 11, 2017**

**Session 4D (3:00 to 4:20)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 to 3:20</td>
<td>Utilization of Patient Satisfaction Metrics for Quality Improvement of Clinic Based MTM Services</td>
<td>Christine Larsen (PGY1), FirstLight Health System - Mora, MN</td>
</tr>
<tr>
<td>3:20 to 3:40</td>
<td>Impact of Pharmacist Comprehensive Medication Reviews on a Health-System Medicare Plan</td>
<td>Ashley Evans (PGY2), CoxHealth - Springfield, MO</td>
</tr>
<tr>
<td>3:40 to 4:00</td>
<td>Pharmacist Impact on Information Exchange and Collaboration Management of a Clinic Formulary System</td>
<td>Margaret Ladlie (PGY2), CoxHealth - Springfield, MO</td>
</tr>
<tr>
<td>4:00 to 4:20</td>
<td>Evaluation of Pharmacist-Provided Comprehensive Medication Review for Patients Receiving Oral Chemotherapy Treatment</td>
<td>Mark乙b套 (PGY2), CoxHealth - Springfield, MO</td>
</tr>
</tbody>
</table>

**Session 4E (3:00 to 4:20)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 to 3:20</td>
<td>Effects of Immediate-and Extended-Release Amphetamine/Dextroamphetamine on Body Mass Index in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder</td>
<td>Laura Steinauer (PGY1), Mayo Clinic - Rochester, MN</td>
</tr>
<tr>
<td>3:20 to 3:40</td>
<td>Estimated Aluminum Exposure Through Parenteral Nutrition in Neonatal Morbidities</td>
<td>Megan Fortenberry (PGY1), Wesley Medical Center - Wichita, KS</td>
</tr>
<tr>
<td>3:40 to 4:00</td>
<td>Assessing Adherence to New Pediatric Traumatic Brain Injury (TBI) Pathway</td>
<td>Gregory Scott (PGY1), Wesley Medical Center - Wichita, KS</td>
</tr>
<tr>
<td>4:00 to 4:20</td>
<td>Evaluating Therapy in Neonatal Abstinence Syndrome</td>
<td>Long Nguyen (PGY1), University of Iowa Hospitals and Clinics - Iowa City, IA</td>
</tr>
</tbody>
</table>

**Session 4F (3:00 to 4:20)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 to 3:20</td>
<td>Cost Analysis of Intravenous N-Acetylcysteine Use at an Academic Medical Center</td>
<td>Jennifer Wiederrich (PGY1), University of Missouri Health Care - Columbia, MO</td>
</tr>
<tr>
<td>3:20 to 3:40</td>
<td>Evaluation of Pharmacist Involvement in Discharge Medication Reconciliation</td>
<td>Britney Stillmunkes (PGY1), Mercy Medical Center - North Iowa - Mason City, IA</td>
</tr>
<tr>
<td>3:40 to 4:00</td>
<td>Central Pharmacy Workflow Analysis and Optimization</td>
<td>Mark Skildum (PGY2), United Hospital - Part of Allina Health - Saint Paul, MN</td>
</tr>
<tr>
<td>4:00 to 4:20</td>
<td>Development and Feasibility of a Pharmacist-Hospitalist Collaborative Role to Improve Medication Utilization at Park Nicollet Methodist Hospital: A Medication Safety Improvement Pilot</td>
<td>Chrissy Czycalla (PGY1), Park Nicollet Methodist Hospital - St. Louis Park, MN</td>
</tr>
</tbody>
</table>

**Session 4G (3:00 to 4:20)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 to 3:20</td>
<td>Evaluating the Use of Appropriate Anticoagulation with Lenalidomide and Pomalidomide in Patients with Multiple Myeloma</td>
<td>Sarah Anderson (PGY1), Avera McKennan Hospital &amp; University Health Center - Sioux Falls, SD</td>
</tr>
<tr>
<td>3:20 to 3:40</td>
<td>Comparison of mTOR Inhibitor Associated Stomatitis Rates in Oncology Patients Initiating Everolimus Treatment with and without Use of Prophylactic Steroid-Based Mouthwash: A Case-Control Study</td>
<td>Ashley Losing (PGY2), Avera McKennan Hospital &amp; University Health Center - Sioux Falls, SD</td>
</tr>
<tr>
<td>3:40 to 4:00</td>
<td>Incidence of Appropriate Monitoring, Adverse Effect Rates, and Management of Programmed Cell Death-1 Receptor and Programmed Cell Death-1 Ligand Inhibitor Therapy in an Oncology Clinic</td>
<td>Christine McNamara (PGY1), Avera McKennan Hospital &amp; University Health Center - Sioux Falls, SD</td>
</tr>
<tr>
<td>4:00 to 4:20</td>
<td>“Tbo-filgrastim versus Filgrastim for Stem Cell Mobilization and Engraftment in Hematopoietic Stem Cell Transplant Patients at Avera McKennan Hospital and University Health Center: A Retrospective Review”</td>
<td>Ashley Potter (PGY2), Avera Cancer Institute - Sioux Falls, SD</td>
</tr>
</tbody>
</table>

**Session 4H (3:00 to 4:20)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 to 3:20</td>
<td>Implementation of a Heart Failure Dashboard for Primary Care Pharmacists to Identify Sub-Optimal Guideline-Directed Medical Therapies in Patients with Heart Failure Reduced Ejection Fraction</td>
<td>Travis Liebhard (PGY1), Minneapolis Veterans Affairs Health Care System - Minneapolis, MN</td>
</tr>
<tr>
<td>3:20 to 3:40</td>
<td>Screening Patient ASCVD Risk by Inputting Optimum Lipid Levels into Pooled Cohorts Equation</td>
<td>Jacqueline Hjelle (PGY1), Thrifty White Pharmacy - Fargo, ND</td>
</tr>
<tr>
<td>3:40 to 4:00</td>
<td>Compliance with the ACC/AHA 2013 Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults</td>
<td>Stephanie Seibel (PGY1), CHI St. Alexius Health - Bismarck, ND</td>
</tr>
<tr>
<td>4:00 to 4:20</td>
<td>Assessment of BMI Impact on Time to Therapeutic Range of Heparin</td>
<td>Kari Righter (PGY1), Southeast Hospital - Cape Girardeau, MO</td>
</tr>
</tbody>
</table>
23
THURSDAY, MAY 11, 2017

Session 5E (4:30 to 5:30)  Big Blue B  Internal Medicine

4:30 to 4:50  "Retrospective Study of the Impact of Pharmacist and Nurse Practitioner Run Preoperative Pain Consult"  
Muong Yu and Valerie Milazzo (PGY1), University of Minnesota Medical Center - Minneapolis, MN

4:50 to 5:10  "Hypoglycemia During Hospitalization and Ways to Prevent It"  
Kristie Holbrook (PGY1), Fairview Ridges Hospital - Burnsville, MN

5:10 to 5:30  "Classification of Medication Changes after Roux-en-Y Gastric Bypass or Sleeve Gastrectomy: A Focus on Narrow Therapeutic Index and High-Risk Drugs"  
Kayla Popova (PGY1), University of Minnesota Medical Center - Minneapolis, MN

Program Objectives:
1. Identify recommendations from the American Pain Society's Guidelines on the Management of Postoperative Pain that can be used by a preoperative pain consult service to help patients improve function and better manage postoperative pain.
2. Identify oral and injectable anti-diabetic medications that put diabetes patients at higher risk for hypoglycemia while NPO status.
3. Describe the proposed pharmacokinetic changes that may occur in patients postoperatively after bariatric surgery.

Session 5F (4:30 to 5:30)  Big Blue C  Clinical Services Management

4:30 to 4:50  "Bypassing Pharmacy Verification in the Emergency Department: Analysis of Autoverified Medication Orders in the ED at St. Luke's"  
Kyle Walker (PGY1), St. Luke's - Duluth, MN

4:50 to 5:10  "Improved Patient Care with Pharmacist Directed Interventions in the Emergency Department of a Community Hospital"  
Amber Yaeger (PGY1), Rapid City Regional Hospital - Rapid City, SD

5:10 to 5:30  "Implementation of Strategies To Reduce Alert Fatigue Associated With Electronic Order Entry In A Children's Hospital"  
Christine Hughes (PGY1), Children's Hospital at Saint Francis - Tulsa, OK

Program Objectives:
1. The audience will be able to identify which types of orders may be appropriate for autoverification.
2. Recognize the impacts on patient care a pharmacist provides while available in the emergency department.
3. Describe processes to reduce alerts within an EHR.

Session 5G (4:30 to 5:30)  Council Bluffs A  Pediatrics/Neonatology

4:30 to 4:50  "Smart Pumps to the Limit"  
Erin DeBoett (PGY1), Children's Hospital and Medical Center - Omaha, NE

4:50 to 5:10  "Evaluating the Outcomes of Infants Before and After Implementation of a Standardized Treatment Protocol for Neonatal Abstinence Syndrome: A Quality Improvement Project"  
Siera Zimmerman (PGY1), Trinity Health - Minot, ND

5:10 to 5:30  "Antenatal Opiate Exposure and Effects on Neonatal Outcomes: Observations at a Community Birth Center"  
Brianne Sutherland (PGY1), Shawnee Mission Medical Center - Shawnee Mission, KS

Program Objectives:
1. Identify potential risks of overriding pump parameters or entering medication administration information as volume over time when the hard limit is reached.
2. Identify important characteristics of an effective treatment protocol.
3. Describe the signs and symptoms of neonatal abstinence syndrome.

Session 5H (4:30 to 5:30)  Council Bluffs B  Cardiology

4:30 to 4:50  "Effects of Doxycycline Use on Gastrointestinal Bleeding Rates In Patients With Continuous-Flow Left Ventricular Assist Devices"  
Kent Botkin (PGY1), Barnes-Jewish Hospital - St. Louis, MO

4:50 to 5:10  "Impact of the Timing of P2Y12 Inhibitor Loading Dose on Recurrent Cardiac Events and Patient Outcomes"  
Hannah Stonewall (PGY1), Nebraska Medicine - Omaha, NE

5:10 to 5:30  "Management of Bleeding Complications in Patients on Oral Anticoagulants: A National Survey of US Hospitals and Institutions"  
Tessa Wiley (PGY1), Nebraska Medicine - Omaha, NE

Program Objectives:
1. Identify the mechanisms by which patients with continuous-flow left ventricular assist devices develop gastrointestinal bleeding.
2. Explain the importance of P2Y12 inhibitor loading dose timing in the setting of PCI as it relates to patient outcomes.
3. Describe the current management of major life-threatening bleeds complicated by oral anticoagulation.

Session 5I (4:30 to 5:30)  Missouri  Primary/Ambulatory Care

4:30 to 4:50  "Incorporating Pharmacy Services Into Ambulatory Care, A Pilot Study"  
Amanda Beck (PGY2), Houston Methodist Hospital - Houston, TX

4:50 to 5:10  "Defining Your Value as an Academic Medical Center Specialty Pharmacy"  
Angelica Costanzo (PGY2), The University of Kansas Health System - Kansas City, KS

5:10 to 5:30  "Potential Impact and Implementation of a Pharmacist in a Rheumatology Clinic"  
Kevin Mahler (PGY1), The University of Kansas Health System - Kansas City, KS

Program Objectives:
1. Explain the incorporation of clinical pharmacy services into a medical-resident ambulatory care clinic.
2. Identify outcomes that can be reported to payers to demonstrate the potential value and impact of an academic medical center specialty pharmacy model.
3. Describe the role of a clinical pharmacist in a specialty clinic.

Session 5J (4:30 to 5:30)  Platte  Critical Care

4:30 to 4:50  "Effect of Quetiapine on Total Ventilator Time and Intensive Care Unit Length of Stay in Trauma Patients"  
Lance Schneider (PGY1), CoxHealth - Springfield, MO

4:50 to 5:10  "Impact of Alvimopan on Gastrointestinal Recovery Time Following Open Ventral Hernia Repair Procedures"  
Sara Wirth (PGY1), CoxHealth - Springfield, MO

5:10 to 5:30  "Effect of a Pharmacist Driven Inpatient Medication Therapy Management Protocol on Glycemic Control in the Critically Ill"  
Shelbie McCoy (PGY2), CoxHealth Medical Center South - Springfield, MO

Program Objectives:
1. Discuss indications for use of quetiapine in ICU patients.
2. Describe the role of alvimopan in preventing postoperative ileus after abdominal surgeries.
3. Understand safety & efficacy impact that a pharmacist driven MTM protocol has on glycemic control in intensive care patient & recognize potential interventions to achieve blood glucose < 180 mg/dl.
2. Discuss the studies and quality of evidence currently available assessing the effects of adjunctive corticosteroids for the treatment of Pneumocystis pneumonia in patients without HIV.

Program Objectives:
1. Identify the seven core elements of antibiotic stewardship programs in nursing homes.
2. Explain possible complications involved in carotid artery stenting.

1. List the appropriate AED (anti-epileptic drug) options used during the "emergent" and "urgent" phases of therapy when treating a patient in SE (status epilepticus).

Program Objectives:
1. Explain the potential association of cardiovascular outcomes with statin monotherapy or concomitant statin and fish oil therapy.
2. Identify potential risks associated with anticoagulation in patients with a left ventricular assist device.

Program Objectives:
1. Identify HF patients not receiving appropriate doses of guideline directed medical therapies and review appropriate laboratory data to determine if further titration of medications is warranted.
2. Identify the importance of identifying a surrogate marker to use to measure rivaroxaban and apixaban activity in certain circumstances.
3. Identify roles of clinical pharmacists in antibiotic stewardship initiatives at Covenant Medical Center.

Program Objectives:
1. Identify the seven core elements of antibiotic stewardship programs in nursing homes.
2. Explain possible complications involved in carotid artery stenting.

Program Objectives:
1. Identify roles of clinical pharmacists in antibiotic stewardship initiatives at Covenant Medical Center.

Program Objectives:
1. Identify HF patients not receiving appropriate doses of guideline directed medical therapies and review appropriate laboratory data to determine if further titration of medications is warranted.
2. Identify the importance of identifying a surrogate marker to use to measure rivaroxaban and apixaban activity in certain circumstances.
3. Identify roles of clinical pharmacists in antibiotic stewardship initiatives at Covenant Medical Center.

Program Objectives:
1. Identify the seven core elements of antibiotic stewardship programs in nursing homes.
2. Explain possible complications involved in carotid artery stenting.

Program Objectives:
1. Identify HF patients not receiving appropriate doses of guideline directed medical therapies and review appropriate laboratory data to determine if further titration of medications is warranted.
2. Identify the importance of identifying a surrogate marker to use to measure rivaroxaban and apixaban activity in certain circumstances.
3. Identify roles of clinical pharmacists in antibiotic stewardship initiatives at Covenant Medical Center.

Program Objectives:
1. Identify the seven core elements of antibiotic stewardship programs in nursing homes.
2. Explain possible complications involved in carotid artery stenting.

Program Objectives:
1. Identify HF patients not receiving appropriate doses of guideline directed medical therapies and review appropriate laboratory data to determine if further titration of medications is warranted.
2. Identify the importance of identifying a surrogate marker to use to measure rivaroxaban and apixaban activity in certain circumstances.
3. Identify roles of clinical pharmacists in antibiotic stewardship initiatives at Covenant Medical Center.

Program Objectives:
1. Identify the seven core elements of antibiotic stewardship programs in nursing homes.
### Program Objectives:

1. Describe the benefits of implementing a robust controlled substance diversion prevention program.

### Session 5I (7:50 to 8:50)  

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:50</td>
<td>Evaluation of Carbapenem Use in Hematology/Oncology Patients at an Academic Medical Center</td>
<td>DENAE BECKMAN (PGY1), NEBRASKA MEDICINE - OMAHA, NE</td>
</tr>
<tr>
<td>8:10</td>
<td>Pharmacists’ Interventions on Chemotherapy Treatment Plans and Supportive Care Therapy Plans in the Ambulatory and Inpatient Care Settings</td>
<td>ANGELA RONDON-BEGAZO (PGY1), NEBRASKA MEDICINE - OMAHA, NE</td>
</tr>
<tr>
<td>8:30</td>
<td>Risk Factors Associated with Steroid-Refractory Acute Graft versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation</td>
<td>JARED MATYA (PGY1), NEBRASKA MEDICINE - OMAHA, NE</td>
</tr>
</tbody>
</table>

### Session 6J (7:50 to 8:50)  

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00</td>
<td>Use of Rapid Diagnostics to Improve Time to Appropriate Antibiotic Therapy for Staphylococcus Aureus Bacteremia</td>
<td>KATHRYN SMITH (PGY1), VISITI HOSPITALS WICHITA, INC. - WICHITA, KS</td>
</tr>
<tr>
<td>9:20</td>
<td>Influence of Parenteral Antibiotics on the Rate of Antibiotic-Associated Diarrhea in Patients Discharged from the Emergency Department</td>
<td>CLAIRE LARSON (PGY1), SANFORD USD MEDICAL CENTER - SIOUX FALLS, SD</td>
</tr>
<tr>
<td>9:40</td>
<td>Antimicrobial Stewardship in Critically III Patients Diagnosed with Pneumonia: a Comparative Evaluation of an Integrated Health Care System’s Practice</td>
<td>JENNIFER DOUGHTY (PGY1), STORMONT VAIL HEALTH - TOPEKA, KS</td>
</tr>
<tr>
<td>10:00</td>
<td>The Impact of Alcohol Abuse on Mortality Following Hepatitis C Treatment with Direct-Acting Antivirals: A National Cohort Study of Veterans Affairs Patients</td>
<td>MICHAEL BUCK (PGY1), VA EASTERN KANSAS HEALTHCARE SYSTEM - TOPEKA, KS</td>
</tr>
<tr>
<td>10:20</td>
<td>Assessment of Reflex Urine Culture Criteria Changes and its Impact on Treatment of Asymptomatic Bacteriuria</td>
<td>KIRRE WOLD (PGY2), MERCY MEDICAL CENTER DES MOINES - DES MOINES, IA</td>
</tr>
</tbody>
</table>

### Program Objectives:

1. Discuss the incidence of antimicrobial resistance in hematology/oncology patients.
2. Identify CPPE related issues that impact the chemotherapy ordering and verification process & discuss monetary value provided by the pharmacists’ interventions.
3. Describe the importance of identifying patients at risk for steroid-refractory acute graft versus host disease.

### Session 7A (9:00 to 10:40)  

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00</td>
<td>Evaluation of the Effectiveness of Phenobarbital in the Treatment of Alcohol Withdrawal Syndrome in the Intensive Care Unit</td>
<td>NICK GOEDEN (PGY1), UNIVERSITY OF MINNESOTA MEDICAL CENTER - MINNEAPOLIS, MN</td>
</tr>
<tr>
<td>9:20</td>
<td>Outpatient Pharmacist-led Anticoagulation Management in Patients with Left Ventricular Assist Devices: A Pilot Study</td>
<td>TAILL SMITH (PGY1), MERCY MEDICAL CENTER DES MOINES - DES MOINES, IA</td>
</tr>
<tr>
<td>9:40</td>
<td>Retrospective Analysis of Piperacillin in Pulmonary Fibrosis Patients</td>
<td>LAUREN BRICKER (PGY1), CLEIGHTON UNIVERSITY MEDICAL CENTER - OMAHA, NE</td>
</tr>
<tr>
<td>10:00</td>
<td>Analysis of Moxidron to Decrease Norepinephrine Requirements in Intensive Care Patients</td>
<td>PATRICK CHADD ENRIQUEZ (PGY1), CHI HEALTH CLEIGHTON UNIVERSITY MEDICAL CENTER - OMAHA, NE</td>
</tr>
<tr>
<td>10:20</td>
<td>Norepinephrine Infusion Outside of the ICU in Open-Heart Surgery Patients</td>
<td>BRADLEY BINGHAM (PGY1), MOSAIC LIFE CARE - ST. JOSEPH, MO</td>
</tr>
</tbody>
</table>

### Program Objectives:

1. Outline the potential benefits of adding phenobarbital to a benzodiazepine driven AWS treatment regimen.
2. Identify unique challenges of warfarin management in patients with left-ventricular assist devices.
3. Describe how piperacillin influences the progression of pulmonary fibrosis and is tolerated by patients.
4. Review the rationale of using adjunctive oral moxidron to facilitate IV NE discontinuation and identify potential benefits associated with its use.
5. Attendees should be able to identify patients who may be eligible to leave the ICU early on a stable-dose norepinephrine infusion.
### Program Objectives:
1. Identify a risk factor which is most likely to cause supratherapeutic troughs in obese patients.
2. According to the 2017 ADA guidelines, define the recommended fasting or pre-prandial blood glucose range for hemoglobin A1c goals of <7%, <7.5% and <8%.
3. Identify key interventions pharmacists can provide while completing medication reconciliation.
4. Understand the role and impact pharmacists have in an underserved primary care clinic.
5. Recognize CDC Guidelines to determine when pneumococcal, tetanus/diphtheria/pertussis, shingles and influenza vaccinations are indicated for patients.

### Session 7C (9:00 to 10:40)  Pharmacy Practice

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 to 9:20</td>
<td>Michael Jacobsen (PGY1)</td>
<td>Implementation of Vancomycin Dosing Protocol Specific for Obese Patients*</td>
</tr>
<tr>
<td>9:20 to 9:40</td>
<td>Samantha Gripska (PGY1)</td>
<td>Developing the Framework to Bill for Inpatient Pharmacist Medication Therapy Services in an Urban Acute-Care Academic Center*</td>
</tr>
<tr>
<td>9:40 to 10:00</td>
<td>Blake Baumann (PGY1), Saint Luke's Hospital of Kansas City - Kansas City, MO</td>
<td>Assessment of Albumin Use in Patients Experiencing Intradialytic Hypotension*</td>
</tr>
<tr>
<td>10:00 to 10:20</td>
<td>Rexford Rodenborn (PGY1), Nebraska Methodist Hospital - Omaha, NE</td>
<td>Utilizing an Electronic Health Record to Improve Pneumococcal Vaccination Rates</td>
</tr>
<tr>
<td>10:20 to 10:40</td>
<td>Andy Bui (PGY1), Houston Methodist Hospital - Houston, TX</td>
<td>Prevalence of Cognitive Impairment in Elderly Patients within 24 Hours of Hospital Admission Utilizing the Mini-Cog*</td>
</tr>
</tbody>
</table>

### Session 7D (9:00 to 10:40)  Primary/Ambulatory Care

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 to 9:20</td>
<td>Alexis Thomas (PGY1), Veterans Affairs Nebraska-Western Iowa Healthcare System - Lincoln, NE</td>
<td>Appropriate Use of Gemfibrozil Therapy within Veteran's Affairs Nebraska-Western Iowa Healthcare System (VA NWI HCS)*</td>
</tr>
<tr>
<td>9:20 to 9:40</td>
<td>Elizabeth Glynn (PGY1), Mercy Medical Center - Cedar Rapids, IA</td>
<td>Implementation of Pharmacist-Led Medication Reconciliation for Pre-Operative Total Hip and Knee Replacement Patients*</td>
</tr>
<tr>
<td>9:40 to 10:00</td>
<td>Brittany Dougherty (PGY1), Mercy Medical Center - Cedar Rapids, IA</td>
<td>Evaluation of Pharmacist Role in Underserved Primary Care Clinic*</td>
</tr>
<tr>
<td>10:00 to 10:20</td>
<td>Laura Martin (PGY1), Laura Martin - Brookings, SD</td>
<td>Utility of a Patient Vaccination Questionnaire to Increase Vaccination Rates*</td>
</tr>
</tbody>
</table>

### Session 7E (9:00 to 10:40)  Internal Medicine

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 to 9:20</td>
<td>Lisa Dykes (PGY1), Iowa City VA Health Care System - Iowa City, IA</td>
<td>Sepsis Redefined: Using New Criteria to Guide Clinical Practice and Outcomes*</td>
</tr>
<tr>
<td>9:20 to 9:40</td>
<td>Tyler Sandahl (PGY1), Iowa City VA Health Care System - Iowa City, IA</td>
<td>Risk Prediction Models for Hospital Acquired Acute Kidney Injury in an Inpatient Veteran Population</td>
</tr>
<tr>
<td>9:40 to 10:00</td>
<td>Olivia Lehman (PGY1), Mercy Medical Center - North Iowa - Mason City, IA</td>
<td>Surviving Sepsis Quality Improvement*</td>
</tr>
<tr>
<td>10:00 to 10:20</td>
<td>Rexford Rodenborn (PGY1), Nebraska Methodist Hospital - Omaha, NE</td>
<td>An Evaluation of Alteplase and Central Lines*</td>
</tr>
<tr>
<td>10:20 to 10:40</td>
<td>Abigail Passe (PGY1), Sanford USD Medical Center - Sioux Falls, SD</td>
<td>Impact of an Orderset on Intravenous Acetaminophen Use in a Hospital Setting*</td>
</tr>
</tbody>
</table>

### Session 7F (9:00 to 10:40)  Clinical Services Management

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 to 9:20</td>
<td>Lauren Aversman (PGY1), Lawrence Memorial Hospital - Lawrence, KS</td>
<td>The Spine Surgery Patient: Expanding the Clinical Pharmacist Role in Perioperative Medication Management and Pain Control</td>
</tr>
<tr>
<td>9:20 to 9:40</td>
<td>Dusti Henrichs (PGY2), The University of Kansas Health System - Kansas City, KS</td>
<td>Implementation of Pharmacist Training to Minimize Health Literacy Disparities and Enhance Patient Understanding of Health Information*</td>
</tr>
<tr>
<td>9:40 to 10:00</td>
<td>Jeffrey Pilz (PGY2), The University of Kansas Health System - Kansas City, KS</td>
<td>Implementation and Analysis of Productivity Tracking Measures in a Network of Outpatient Oncology Infusion Centers</td>
</tr>
<tr>
<td>10:00 to 10:20</td>
<td>Megan Williams (PGY1), Wesley Medical Center - Wichita, KS</td>
<td>Provider Utilization Of Pharmacy Progress Notes Within A Computerized Physician Order Entry System</td>
</tr>
</tbody>
</table>

### Program Objectives:
1. Recognize the differences between the current and former definitions surrounding sepsis.
2. Identify common risk factors associated with development of hospital acquired acute kidney injury.
3. Describe the four treatment measures CMS assesses to determine compliance with the sepsis 3-hour bundle.
4. Discuss the role of alteplase for occluded central lines.
5. Discuss the impact of the use of intravenous acetaminophen in a hospital setting.
Session 7G (9:00 to 10:40)

Council Bluffs A

**Program Objectives:**
1. Describe infection prophylaxis regimens in patients with lymphoma undergoing chemotherapy at an academic medical center.
2. Identify the risks versus benefits of levofloxacin prophylaxis in autologous HSCT recipients.
3. Describe the possible manifestations of vincristine-induced neurotoxicity.
4. Discuss the utilization of an adjusted body surface area dosing scheme for bortezomib in obese patients post autologous hematopoietic stem cell transplant.
5. Summarize the most common immune-related adverse events associated with checkpoint inhibitors and identify appropriate management strategies.

**Council Bluffs B**

**Program Objectives:**
1. Identify potential benefits of transitioning a patient to oral antibiotic therapy.
2. Select the most appropriate empiric antibiotic regimen for a young, healthy female diagnosed with a urinary tract infection with no contraindications to treatment.
3. Discuss warfarin requirements in post cardiac surgery populations.
4. Evaluate the mechanism through which serotonin-norepinephrine reuptake inhibitors may have negative impact on those with heart failure.
5. Review the indication and role for proton pump inhibitor use in patients with dual antiplatelet therapy.

Session 7H (9:00 to 10:40)

**Program Objectives:**
1. Describe the impact of pharmacist-led education and follow up on 30 day readmission rates.
2. Characterize differences, if present, in vasopressor use in patients bridged to cardiac transplant with LVADs or medical management.
3. Discuss warfarin requirements in post cardiac surgery populations.
4. Evaluate the mechanism through which serotonin-norepinephrine reuptake inhibitors may have negative impact on those with heart failure.
5. Review the indication and role for proton pump inhibitor use in patients with dual antiplatelet therapy.

Session 7I (9:00 to 10:40)

Missouri

**Program Objectives:**
1. Identify appropriate dosing strategies for beta-lactam antibiotics based on MIC distribution data for key pathogens within a facility.
2. Select the most appropriate empiric antibiotic regimen for a young, healthy female diagnosed with a urinary tract infection with no contraindications to treatment.
3. Discuss the intent and implementation of various targeted Antimicrobial Stewardship Program initiatives designed to reduce fluoroquinolone use in a community hospital.
4. Explain risk factors for developing Clostridium difficile in patients with orthopedic infections.

Session 7J (9:00 to 10:40)

Platte

**Program Objectives:**
1. Identify potential benefits of transitioning a patient to oral antibiotic therapy.
2. Identify benefits and downsides of using qSOFA or SIRS in screening patients for sepsis.
3. Identify and discuss the risk for hemorrhagic conversion after ITPA for ischemic stroke in patient receiving concomitant pharmacologic VTE prophylaxis.
5. Discuss the use of anti-epileptic drugs (AEDs) for seizure prophylaxis in patients with traumatic brain injury (TBI) or intracranial hemorrhage (ICH).

Session 7K (10:50 to 12:10)

Elkhorn A

**Program Objectives:**
1. To assess whether this alternative meropenem dosing strategy achieves similar clinical outcomes to manufacturer-recommended meropenem dosing.
2. Recognize common pharmacist interventions supported by an interdisciplinary antimicrobial stewardship team.
3. Identify the benefits to incorporating rapid diagnostic testing and antimicrobial stewardship staff regarding positive blood cultures.
4. Discuss patient population that would qualify for implemented novel dosing strategy.
### Program Objectives:

1. Describe the incidence of bleeding events in patients receiving anticoagulation with ELSO recommended ACT goals compared to non-ELSO recommended ACT goals.
2. Describe the methods used to prevent hypoglycemia and other adverse events associated with insulin infusions.
3. Compare the prevalence of cardiovascular compromise in CVICU patients receiving dexmedetomidine or propofol.
4. Recognize the rationale behind low dose naloxone for opioid induced respiratory depression.

### Program Objectives:

1. Identify the pharmacy services implemented and the benefits of an Enhanced Recovery Program for patients undergoing colorectal surgery.
2. Identify the impact of a pharmacist's involvement in the discharge medication reconciliation process.
3. Identify patient characteristics that an inpatient pharmacist can utilize to identify patients who would benefit from a referral to an outpatient pharmacist clinician.

### Program Objectives:

1. Evaluate the finding of the SAVOR-TIMI 53 clinical trial that has led to the specific primary aim of this study.
2. Describe the Integrative Health services that are offered at the Sioux Falls VA Health Care System and how participation in these services impacted Veteran's average daily opioid dose.
3. Recognize key factors that must be considered when ensuring appropriate prescribing of DOAC medications.

### Program Objectives:

1. Recall the recommended monitoring parameters for sotalol initiation.
2. Identify and improve inappropriate selection and monitoring of antiarrhythmic medications based on patient specific factors as set forth by current guideline recommendations.
3. Describe patient populations and associated dosing regimens of therapeutic enoxaparin which increase the risk of bleeding.
4. Describe prescribing patterns for choice and dosing of oral anticoagulation therapy in patients with AF and ESRD receiving hemodialysis.

### Program Objectives:

1. Recognize key factors that must be considered when ensuring appropriate prescribing of DOAC medications.
2. Describe the integrative health services that are offered at the Sioux Falls VA Health Care System and how participation in these services impacted Veteran's average daily opioid dose.
3. Explain the finding of the SAVOR-TIMI 53 clinical trial that has led to the specific primary aim of this study.

### Program Objectives:

1. Evaluate the incidence of Dexmedetomidine Withdrawal Syndrome in Adult Intensive Care Unit Patients Following Prolonged Infusions.
2. Discuss the effects of fever in aneurysmal subarachnoid hemorrhage patients.
3. Identify the risks associated with agents used for SUP and report the impact of a SUP protocol.
4. Identify what effect prolonged infusions of dexmedetomidine has on blood pressure and heart rate upon abrupt discontinuation.
**Session 8A (10:50 to 12:10)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenters</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:50 to 11:10</td>
<td>&quot;Effect of a Community Pharmacy Self-Referral Transitions of Care Service on 30-Day Hospital Readmission Rates&quot;</td>
<td>Frank Fanizza (PGY1), Balls Food Stores/University of Kansas School of Pharmacy - Olathe, KS</td>
<td>Council Bluffs A Community Practice</td>
</tr>
<tr>
<td>11:10 to 11:30</td>
<td>&quot;Assessing Pet Owner and Veterinarian Perceptions of Need for Veterinary Compounding Services in a Community Pharmacy Setting&quot;</td>
<td>Shelby Bennett (PGY1), Price Chopper Pharmacy - Overland Park, KS</td>
<td></td>
</tr>
<tr>
<td>11:30 to 11:50</td>
<td>&quot;Community Pharmacist-Managed Medication Reconciliation Program in Transitions of Care: A Pilot Study to Assess Program Feasibility&quot;</td>
<td>Christa Tetuan (PGY1), University of Missouri - Kansas City and Red Cross Pharmacy - Excelsior Springs, MO</td>
<td></td>
</tr>
<tr>
<td>11:50 to 12:10</td>
<td>&quot;Identification of Medication-Related Problems by Community Pharmacists in Patients with Chronic Inflammatory Diseases&quot;</td>
<td>Robert Keane (PGY1), University of Missouri Kansas City - Kansas City, MO</td>
<td></td>
</tr>
</tbody>
</table>

**Program Objectives:**
1. Describe the outcomes of drug therapy problems identified by community pharmacists after a transitions of care comprehensive medication review.
2. Identify pet owner- and veterinarian-perceived benefits and barriers of veterinary compounding services in a community pharmacy.
3. Indicate the key steps involved in the service model created by Red Cross Pharmacy and Fitzgibbon Hospital.
4. Describe medication related problems identified in this patient population including both medications to treat chronic inflammatory diseases and those related to co-morbid conditions.

---

**Session 8B (10:50 to 12:10)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenters</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:50 to 11:10</td>
<td>&quot;Effects of Pharmacist Intervention at Hospital Discharge and Follow-Up&quot;</td>
<td>Landon Weaver (PGY1), University of Minnesota/CentraCare Health - Saint Cloud, MN</td>
<td>Council Bluffs B Primary/Ambulatory Care</td>
</tr>
<tr>
<td>11:10 to 11:30</td>
<td>&quot;Use of Routine Assessment of Patient Index Data (Rapid-3) for Patients with Rheumatoid Arthritis as a Novel Approach to Tracking Disease Activity Levels&quot;</td>
<td>Jacob Hansen (PGY1), Fairview - Minneapolis, MN</td>
<td></td>
</tr>
<tr>
<td>11:30 to 11:50</td>
<td>&quot;Effect of Pharmacist Directed Education for Healthcare Workers on Pneumococcal Vaccination Rates in Outpatient Clinics&quot;</td>
<td>Stacy Reid (PGY1), Via Christi Hospitals Wichita, Inc. - Wichita, KS</td>
<td></td>
</tr>
<tr>
<td>11:50 to 12:10</td>
<td>&quot;Improving Hypertension Management through Population Health Statistics: A Team Approach&quot;</td>
<td>Elizabeth Bedel (PGY2), Kansas City Veterans Affairs Medical Center - Kansas City, MO</td>
<td></td>
</tr>
</tbody>
</table>

**Program Objectives:**
1. Recognize challenges to implementing pharmacist-led medication education at the time of discharge.
2. Describe current adherence trends among rheumatoid arthritis patients within a specialty pharmacy and identify the relationship between these trends and disease activity.
3. Recognize the appropriate pneumococcal vaccine to be administered based on patient specific factors.
4. Recognize first-line antihypertensive medications recommended by JNC 8 Hypertension Guidelines.

---

**Session 8I (10:50 to 11:30)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenters</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:50 to 11:10</td>
<td>&quot;Antineoplastic Agents Given Towards End-of-life in Stage IV Solid Tumors&quot;</td>
<td>Lindsay Edmondson (PGY2), Houston Methodist Hospital - Houston, TX</td>
<td>Missouri Hematology/Oncology</td>
</tr>
<tr>
<td>11:10 to 11:30</td>
<td>&quot;Characterization of Chemotherapy-induced Peripheral Neuropathy: A Prospective Pilot Study&quot;</td>
<td>Veronica Ajewole (PGY2), Houston Methodist Hospital - Houston , TX</td>
<td></td>
</tr>
</tbody>
</table>

**Program Objectives:**
1. Evaluate the use of antineoplastic agents in the last 2 weeks of life in patients with metastatic solid tumors at a large academic hospital.

**Session 8J (10:50 to 11:30)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenters</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:50 to 11:10</td>
<td>&quot;Launching a Pharmacy Technician-led Medication History Service&quot;</td>
<td>Sasha Haarberg (PGY1), CHI Health-St. Elizabeth - Lincoln, NE</td>
<td>Platte Clinical Services Management</td>
</tr>
<tr>
<td>11:10 to 11:30</td>
<td>&quot;Evaluation of Outcomes Associated with Exparel (liposomal bupivacaine) Utilization in Intra-Abdominal Surgeries: A Retrospective Review&quot;</td>
<td>Natalie Gadbois (PGY1), Iowa Methodist Medical Center - Des Moines, IA</td>
<td></td>
</tr>
</tbody>
</table>

**Program Objectives:**
1. Discuss the impact on accuracy and productivity the implementation of medication history technicians have on the medication history process in a community hospital.
2. Discuss approved and appropriate indications for use of Exparel (liposomal bupivacaine).